The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Elderly and younger patients with non-small cell lung cancer (NSCLC) derive similar benefit from second-line chemotherapy: A retrospective subset analysis of second-line chemotherapy trials conducted from the Hellenic Cooperative Research Group (HORG).
Sofia Agelaki
No relevant relationships to disclose
Dora Hatzidaki
No relevant relationships to disclose
Lampros Vamvakas
No relevant relationships to disclose
Athanasios G. Pallis
No relevant relationships to disclose
Athanasios Karampeazis
No relevant relationships to disclose
Athina Agelidou
No relevant relationships to disclose
Maria Agelidou
No relevant relationships to disclose
Vassilis Chandrinos
No relevant relationships to disclose
Aristidis Polyzos
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - Amgen (U); GlaxoSmithKline (U); Janssen-Cilag (U); Novartis (U); Sanofi (U)
Honoraria - Amgen; GlaxoSmithKline; Janssen-Cilag; Novartis; Sanofi
Research Funding - Amgen; GlaxoSmithKline; Janssen-Cilag; Novartis; Sanofi